Navigation Links
Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics

LAUSANNE, Switzerland, July 4, 2013 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.

Under the research framework, Quartz Bio will apply its leading expertise in bioinformatics to support Debiopharm translational projects in terms of computational analyses and biomarker discovery. Projects are expected to range from preclinical Next-Generation Sequencing to clinical biomarker data analyses.

"We are delighted to collaborate with Debiopharm," said Dr. Jerome Wojcik, CEO of Quartz Bio. "Debiopharm's pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of Precision Medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients."

"We look forward to collaborating with Quartz Bio," commented Dr. Hiroaki Tanaka, Director of Personalized Medicine at Debiopharm. "Their longstanding clinical bioinformatics experience made them an ideal partner to support our biomarker projects in our clinical trials and extract from data the relevant information required for personalized therapy development."

About Quartz Bio

Quartz Bio SA is a clinical bioinformatics service company specialized in exploratory biomarker data analyses for the generation of precision medicine hypotheses. Quartz Bio provides modular data analysis solutions to the major steps of the biomarker development process. These include: biomarker study design, biomarker data quality control, statistical analysis and scientific reporting. The capital of the company is entirely owned by its employees, who are scientists from diverse educational backgrounds with a common track record of 6 to 10 years clinical bioinformatics experience in the pharmaceutical sector.

For more information, please visit the company's web site:

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses and develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics to profit from the unique advantages of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™:

Debiopharm International SA Contact
Beatrice Hirt
Communication Coordinator
Tel.: +41-21-321-01-11

Additional Media Contacts
In London
Brian Hudspith
Tel.: +44-(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
2. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
3. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
4. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
5. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
6. Ventana Supports World Patient Safety Day, July 25
7. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
8. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
9. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
10. Henry Schein Cares Supports Alliance for Oral Health Across Borders Leadership Event
11. Cardinal Health Supports Future Pharmacists With Nearly $1 Million In Scholarships
Post Your Comments:
(Date:11/26/2015)... , November 27, 2015 /PRNewswire/ ... --> Medical ... response system (PERS) market is ... 5 years with APAC being ... to see a high CAGR ...
(Date:11/26/2015)... November 26, 2015 --> ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... has found that immunotherapy can be efficiently combined with ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/29/2015)... Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Excellence is once again accredited by the American Institute of Ultrasound in ... that allows practices to demonstrate that they meet or exceed nationally recognized ...
(Date:11/29/2015)... ... 29, 2015 , ... NewsWatch featured X-wing as part of its monthly Tech ... a technology expert and special reporter for NewsWatch, conducted the review and shared with ... It’s the future because flying cars are about to become a reality. Where’s the ...
(Date:11/29/2015)... ... ... Doctors who missed a case of mesothelioma in a 70-year-old Japanese truck driver ... a diagnosis, especially in people exposed to asbestos. Surviving Mesothelioma has just posted details ... , Researchers at Gifu Prefectural Tajimi Hospital in Japan say the patient complained ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated ... announce their December, 2015, featured apartment community: Epic. In showcasing this featured apartment community ... the tight Bay Area rental market to efficiently find housing suitable to their needs ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an ... due to personal experience with a bad back," he said. , This easy-to-use, versatile ... as increases support. It also makes it easier to eat, do other activities and ...
Breaking Medicine News(10 mins):